학술논문

Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors
Document Type
Article
Source
In: Clinical Cancer Research. (Clinical Cancer Research, 1 September 2022, 28(17):3709-3719)
Subject
Language
English
ISSN
15573265
10780432